T
Tejaswitha J. Naik
Researcher at Stanford University
Publications - 2
Citations - 1399
Tejaswitha J. Naik is an academic researcher from Stanford University. The author has contributed to research in topics: CD47 & Cancer. The author has an hindex of 2, co-authored 2 publications receiving 1031 citations.
Papers
More filters
Journal ArticleDOI
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham,Jens Peter Volkmer,Andrew J. Gentles,Debashis Sahoo,Piero Dalerba,Siddhartha Mitra,Jian Wang,Humberto Contreras-Trujillo,Robin Martin,Justin D. Cohen,Patricia Lovelace,Ferenc A. Scheeren,Mark P. Chao,Kipp Weiskopf,Chad Tang,Anne Kathrin Volkmer,Tejaswitha J. Naik,Theresa A. Storm,Adriane Mosley,Badreddin Edris,Seraina Schmid,Chris K. Sun,Mei-Sze Chua,Oihana Murillo,Pradeep S. Rajendran,Adriel C. Cha,Robert K. Chin,Dongkyoon Kim,Maddalena Adorno,Tal Raveh,Diane Tseng,Siddhartha Jaiswal,Per Øyvind Enger,Gary K. Steinberg,Gordon Li,Samuel So,Ravindra Majeti,Griffith R. Harsh,Matt De Van Rijn,Nelson N.H. Teng,John B. Sunwoo,Ash A. Alizadeh,Michael F. Clarke,Irving L. Weissman +43 more
TL;DR: All human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination, showing that CD47 is a commonly expressed molecule on all cancers, its function to blockphagocytosis is known, and blockade of its function leads to tumor cell phagcytosis and elimination.
Journal ArticleDOI
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Nan Guo Ring,Nan Guo Ring,Dietmar Herndler-Brandstetter,Kipp Weiskopf,Liang Shan,Jens Peter Volkmer,Benson M. George,Melanie Lietzenmayer,Mckenna Kelly Marie,Tejaswitha J. Naik,Aaron McCarty,Yunjiang Zheng,Aaron M. Ring,Richard A. Flavell,Richard A. Flavell,Irving L. Weissman +15 more
TL;DR: An anti-human SIRPα antibody, KWAR23, is developed, which in combination with tumor-opsonizing antibodies, greatly augmented neutrophil and macrophage antitumor activity in vitro and in vivo and may represent a promising candidate for combination therapies.